含贝达喹啉长程及短程治疗方案在耐药结核病不同人群中的应用
Application of bedaquiline-containing long-term and short-term treatment regimens used in different populations with drug resistant tuberculosis
胡鑫洋 1雷婧 1高静韬1
作者信息
- 1. 首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所,北京 101149
- 折叠
摘要
耐药结核病是全球面临的重大公共卫生挑战.2018年WHO将贝达喹啉列为耐多药结核病/利福平耐药结核病(multi-drug resistant tuberculosis/rifampicin resistant tuberculosis,MDR/RR-TB)治疗的首选药物之一.近年全球围绕含贝达喹啉不同药物组合及不同疗程的治疗新方案的探索与应用不断积累并迭代了大量循证依据.本文对贝达喹啉在儿童/青少年、孕产妇和老年人等MDR/RR-TB特殊人群以及MDR/RR-TB共患病人群中的有效性及安全性进行综述,以期为其临床应用提供参考.
Abstract
Drug resistant tuberculosis poses a significant global public health challenge.In 2018,World Health Organization(WHO)listed bedaquiline as one of Group A drugs for the treatment of multi-drug resistant tuberculosis/rifampicin resistant tuberculosis(MDR/RR-TB).In recent years,there has been a continuous accumulation of substantial evidence from global exploration and application of new treatment regimens involving bedaquiline in combination with different drugs and duration.The efficacy and safety of bedaquiline in special populations such as children/adolescents,pregnant women,and the elderly,as well as in patients with comorbidities of MDR/RR-TB are reviewed in this article,aiming to provide insights for its clinical application.
关键词
贝达喹啉/耐药结核病/特殊人群/共患病/有效性/安全性Key words
Bedaquiline/Drug-resistant tuberculosis/Special populations/Comorbidity/Efficacy/Safety引用本文复制引用
基金项目
北京市卫生健康委员会高层次公共卫生技术人才培养计划(2022-3-015)
通州区"两高"人才计划(YH201903)
北京市医院管理中心"登峰"人才培养计划(DFL20221401)
出版年
2024
NETL
NSTL
万方数据